First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect
Immunotherapy Advances - ASCO 2020: Key Lung Cancer Studies - Lung Cancer - 2020 ASCO Annual Meeting - Oncology - Clinical Care Options
Comparisons between the CheckMate 227 trial and simulation, overall... | Download Scientific Diagram
ASCO 2020 Lung Cancer Highlights - Journal of Oncology Navigation & Survivorship
Immunotherapy Advances - ASCO 2020: Key Lung Cancer Studies - Lung Cancer - 2020 ASCO Annual Meeting - Oncology - Clinical Care Options
2021 Midyear Review: Non–Small-Cell Lung Cancer | Personalized Medicine in Oncology
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis - The Lancet Oncology
JTO & JTO CRR on Twitter: "In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival versus chemotherapy in patients w/tumor programmed death-ligand 1 greater than or equal to 1% (primary end point)
OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC
First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients - ScienceDirect
ASCO 2020 Lung Cancer Highlights - Journal of Oncology Navigation & Survivorship
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA | SpringerLink
Update Confirms 5-Year Survival Benefit With Dual Immune Checkpoint Blockade in NSCLC
New CheckMate-227 5-Year Data Show Substantial Survival Benefit of Combination Immunotherapy for Metastatic Non–Small Cell Lung Cancer
US regulator scoops Asco with Bristol's lung cancer approval | Evaluate
First-line Nivolumab Plus Ipilimumab is Safe
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer | NEJM
Rapid Readouts: Three-Year Update From CheckMate 227, Part 1
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC | Nature Reviews Clinical Oncology
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer | NEJM
Nivolumab Combined with Ipilimumab
First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients☆ - ESMO Open
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect
